Clinical Trials Sponsored by Vasopharm GmbH

Total 3288 results

Vasopharm GmbH

Completed

Phase 2 a Study to Assess Safety and Pharmacokinetics of VAS203 in Patients With Traumatic Brain Injury (NOSTRA)

Traumatic Brain Injury

Austria, France, Spain, Switzerland, United Kingdom
Vasopharm GmbH
Winicker Norimed GmbH

Completed

Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers

Renal Function Impairment in Healthy Volunteers

Germany
Vasopharm GmbH
ICON plc

Completed

Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury (NOSTRA-III)

Traumatic Brain Injury

United Kingdom, Spain, France, Austria, Germany
Labopharm Inc.

Completed

A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up

Pain | Osteoarthritis, Knee
Labopharm Inc.

Completed

A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol HCl / Contramid® Tablets to Twice Daily Tramadol HCl (SR) for the Treatment of Osteoarthritis of the Knee

Pain | Osteoarthritis, Knee
Labopharm Inc.

Completed

A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee

Pain | Osteoarthritis, Knee
Labopharm Inc.

Completed

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

Major Depressive Disorder

United States, Canada
Labopharm Inc.

Completed

A Study to Compare the Bioavailability of Two Tramadol Hydrochloride Tablet Products (50 mg and 200 mg, Respectively) at Steady-state Under Fasting Conditions

Healthy Subjects | Pharmacokinetics | Bioavailability
Labopharm Inc.

Completed

A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers

Healthy
Labopharm Inc.

Completed

A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain

Acute Low Back Pain

United States, Canada
Labopharm Inc.

Completed

Study of Two Tramadol Contramid® OAD 300 mg Controlled-Release Tablets From Two Different Manufacturing Sites Following a 300 mg Dose in Healthy Subjects Under Fasting and Fed Conditions

Healthy
Labopharm Inc.

Completed

A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets at Steady State

Healthy Subjects | Pharmacokinetics | Bioavailability
Labopharm Inc.

Completed

A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day

Acute Low Back Pain
Labopharm Inc.

Completed

Comparative Bioavailability Study of Two Prototypes of Trazodone Controlled-release Products and Two Marketed Reference Products in Healthy Volunteers

Healthy
Labopharm Inc.

Completed

A Comparative Bioavailability/Food Effect Study of Immediate-Release and Extended-Release Tramadol HCl/Acetaminophen Combination Products Following Single-Dose and Multiple-Dose Administration in Healthy Adult Volunteers

Healthy

United Kingdom
Labopharm Inc.

Completed

A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee (With 7-Day Follow-up)

Pain
Labopharm Inc.

Completed

An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee

Osteoarthritis, Knee
Labopharm Inc.

Completed

A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis

Pain | Osteoarthritis
Labopharm Inc.

Completed

A Study to Compare the Relative Bioavailability of Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions

Healthy
Labopharm Inc.

Completed

A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily)

Healthy
Labopharm Inc.

Completed

Comparative Bioavailability Between Two Tramadol Formulations: Study of the Better Controlled Release of a New 200 mg Once A Day (OAD) Formulation Versus Zytram® 200 mg

Pain
Ascopharm Groupe Novasco

Completed

Open, Multicentric Trial Evaluating the Efficacy and the Clinical Tolerance of PA0903 as Root Canal Sealer (PA0903)

Root Canal Obturation

France, United Kingdom
AIO-Studien-gGmbH
Servier Deutschland GmbH; Crolll Gmbh

Active, not recruiting

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (PREDICT)

Metastatic Pancreatic Cancer | Locally Advanced Pancreatic Cancer

Germany
VisionHealth GmbH
Thoraxklinik-Heidelberg gGmbH

Recruiting

Effects of the Kata® Inhalations-App on Inhaler Handling Errors, Adherence, and Asthma Control in Patients With Asthma.

Asthma

Germany
Clinical Institute of the Brain, Russia
Ever Neuro Pharma GmbH; Nycomed; Veropharm

Completed

Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke. (3C)

Stroke

Russian Federation
AIO-Studien-gGmbH
Pfizer; Crolll Gmbh

Recruiting

Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy (PREPARE)

Renal Cell Carcinoma, Metastatic | Renal Cell Cancer, Recurrent

Germany
AIO-Studien-gGmbH
Celgene; ClinAssess GmbH

Completed

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer (NEONAX)

Resectable Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

Germany
Thoraxklinik-Heidelberg gGmbH
Erbe Elektromedizin GmbH

Completed

EBUS Guided Cryobiopsies With Ultrathin Cryoprobe in Patients With Peripheral Pulmonary Nodules - a Feasibility Study

Transbronchial Cryobiopsy

Germany
AIO-Studien-gGmbH
Sanofi; ClinAssess GmbH

Terminated

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) (CaBaMet)

Breast Cancer | Lung Cancer | Recurrent Brain Metastases | Progressive Brain Metastases

Germany
AIO-Studien-gGmbH
Amgen; ClinAssess GmbH

Completed

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) (VOLFI)

Metastatic Colorectal Cancer

Germany
AIO-Studien-gGmbH
Amgen; ClinAssess GmbH

Completed

Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer (PanaMa)

Metastatic Colorectal Cancer

Germany
WiSP Wissenschaftlicher Service Pharma GmbH
Mundipharma Research GmbH & Co KG; Klinikum Leverkusen gGmbH; ribosepharm GmbH

Completed

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
AIO-Studien-gGmbH
Merck Serono GmbH, Germany

Terminated

Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer (NEOBIL)

Cholangiocarcinoma | Biliary Tract Cancer

Germany
AIO-Studien-gGmbH
Celgene Corporation; ClinAssess GmbH

Completed

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine (ALPACA)

Adenocarcinoma of the Pancreas | Metastatic Pancreatic Cancer

Germany
AIO-Studien-gGmbH
Celgene Corporation; ClinAssess GmbH

Completed

Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer (NEOLAP)

Ductal Adenocarcinoma of the Pancreas

Germany
Pharnext SA
Ascopharm Groupe Novasco

Completed

24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion (PLEODIAL-II)

Alzheimer Disease

France
Labopharm Inc.
Algorithme Pharma Inc

Completed

Comparative Bioavailability Study of Extended-release and Immediate-release Trazodone in Healthy Adult Volunteers

Healthy

Canada
Pharnext SA
Ascopharm Groupe Novasco

Completed

Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD) (PLEODIAL-I)

Alzheimer Disease

France
Ascopharm Groupe Novasco
AscoPharm is conducting the study under the responsibility of SEPTODONT

Completed

Efficacy and the Safety Study of RD94 in Patients With Endodontic Care (RD94)

Tooth Injury

France
Infectopharm Arzneimittel GmbH
Gesellschaft für Therapieforschung mbH

Recruiting

Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood (MOPAD)

Atopic Dermatitis | Infant, Newborn

Germany
Infectopharm Arzneimittel GmbH
Gesellschaft für Therapieforschung mbH

Completed

5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis (KOHDIAK)

Actinic Keratosis

Germany
Infectopharm Arzneimittel GmbH
Gesellschaft für Therapieforschung mbH

Completed

Treatment of Actinic Keratosis With 5% KOH Solution (TAKKOH)

Actinic Keratoses

Germany
AIO-Studien-gGmbH
Amgen; Assign Data Management and Biostatistics GmbH; Assign Clinical Research...

Terminated

Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer (POWER)

Esophageal Squamous Cell Cancer

Germany
AIO-Studien-gGmbH
Universitätsklinikum Hamburg-Eppendorf; Merck Serono GmbH, Germany; Pierre Fabre...

Recruiting

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF)

Colorectal Cancer | Colon Cancer | BRAF V600 Mutation | BRAF V600E | Localized Cancer

Germany
CytoSorbents Europe GmbH
BRAHMS GmbH; MedInnovation GmbH

Recruiting

A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock (PROCYSS)

Septic Shock

Germany
neuroloop GmbH
MAXIS GmbH

Terminated

The Baroloop Study

Hypertension

Netherlands
cortEXplore GmbH
Raffeiner GmbH

Completed

Navigation Support With Mixed Reality With CORTEXPLORER MED (CXmed)

Cranial Aneurysm

Austria
afreeze GmbH
Raffeiner GmbH

Recruiting

Treatment Success With the CoolLoop Cryoablation System

Heart Diseases | Cardiovascular Diseases | Atrial Fibrillation | Arrhythmias, Cardiac | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation

Austria, Germany
Nano4Imaging GmbH
CERES GmbH

Completed

Post-market Clinical Follow-up Study With Magnetic Resonance Imaging Conditional Guide Wire (MRWIREPMCF)

Congenital Heart Defect

Germany, United Kingdom
afreeze GmbH
Accovion GmbH

Terminated

CoolLoop Paroxysmal Atrial Fibrillation (CoolLoop PAF)

Pathologic Processes | Heart Diseases | Cardiovascular Diseases | Arrhythmias, Cardiac | Atrial Fibrillation (Paroxysmal)

Austria, Germany, Switzerland

3

Subscribe